Search

This session will introduce the technique of optogenetics and its potential for development into a treatment for IRDs.

• Webinar
• Video

Jing Yu is a Research Assistant at the Nuffield Department of Clinical Neurosciences at the John Radcliffe Hospital in Oxford.

• Case study - research
• Written

Tomasz Tomkiewicz is undertaking a PhD studentship funded by Retina UK and The Macular Society.

• Case study - research
• Written

Progress towards treatments for inherited retinal conditions continues to gather pace and there’s been lots going on in the last few months, with more and more approaches being explored. This round-up gives a flavour of the variety of developments, including plenty that are not specific to a particular genetic fault.

• News

In April 2022 we joined with another seven leading sight loss organisations to make a public commitment to increasing the number of blind and partially sighted people employed within our sector, including at senior management level.

• News

New Eye Care Support Pathway wins cross-sector backing for transforming the way people with care needs and sight loss are helped emotionally and practically.

• News

Including a gift to Retina UK in your Will is an incredibly special way to help our vital work continue into the future.

These frequently asked questions should provide a response for most of the queries you might raise.

Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.

• FAQ
• Written

Nurturing a new generation of scientists is a vital investment in the future of retinal disease research, so we are delighted to be funding, in collaboration with the Macular Society, a new PhD studentship at Oxford University, supervised by Professor Robert MacLaren.

• Case study - research
• Written